ID: 19386
User updated by: [EMAIL PROTECTED]
Reported By: [EMAIL PROTECTED]
-Status: Feedback
+Status: Open
Bug Type: PCRE related
Operating System: *
PHP Version: 4.2.3, 4.3.0-dev
New Comment:
Tests of different lengths of string '$x' show that if
strlen($x) > 4040 the crash occurs i.e. with the last
text is 'Randomized-Controlled-Trial' php will crash. A
shorter script as requested is:
<?php
$x = '';
while (true) {
$x .= '*';
$len = strlen($x);
preg_match('/(.|[\r\n])+/', $x, $match);
echo "<br />$len\n";
}
?>
Previous Comments:
------------------------------------------------------------------------
[2002-09-13 12:31:15] [EMAIL PROTECTED]
I can reproduce the crash on Linux too. But could you try
shortening the example script to something bit smaller?
------------------------------------------------------------------------
[2002-09-13 09:53:19] [EMAIL PROTECTED]
By php version 4.3.1 I mean 4.2.1 of course ;-)
------------------------------------------------------------------------
[2002-09-13 07:20:54] [EMAIL PROTECTED]
Crash also occurred with php version 4.3.1. Binary windows
version was used in both cases. Doe not occur for all
values of $x (probably only for very long strings ?).
<?php
$x = 'AN 11293237 20010507. AU Kraj, M.; Poglod, R.; Pawlikowski, J.;
Maj, S.; Nasilowska, B. IN Institute of Haematology and Blood
Transfusion, 5 Chocimska Str., 00-957 Warsaw, Poland. TI Effect of
pamidronate on skeletal morbidity in myelomatosis. Part 1. The
results of the first 12 months of pamidronate therapy. SO Acta Pol.
Pharm. IS 0001-6837 YR 2000 VL 57 Suppl PG 113-116 LG English. DE
ADULT; AGED; BONE-RESORPTION/PX (psychology); CALCIUM/UR
(urine); DIPHOSPHONATES/*TU (therapeutic use); FEMALE; HUMAN;
MALE; MIDDLE-AGE; MULTIPLE-MYELOMA/CO (complications), *DT
(drug therapy); OSTEOLYSIS/*PC (prevention & control). RN 0
(Diphosphonates); 40391-99-9 (amidronate); 7440-70-2 (Calcium).
AB BACKGROUND: Osteolytic bone destruction caused by increase
of osteolytic activity is a major manifestation of multiple myeloma
(MM) . Pamidronate
(3-amino-1-hydroxypropylidene)-1,1-bisphosphonate) inhibits
osteoclastic activity and reduces bone resorption. METHODS: Since
October 1995 the efficacy of pamidronate is evaluated in MM
patients all receiving anti-myeloma chemotherapy acc. to VMCP/VBAP
alternating regimen. 46 patients with stage III myeloma and
osteolytic lesions were randomized to receive either pamidronate
(Aredia; Novartis) 60 mg i.v. in 4-hour infusion monthly (n = 23)
or chemotherapy alone (control group n = 23). Estimation of
performance status, quality of life, pain score, analgesic
consumption, serum calcium concentration and twenty four-hours
Calcium excretion, urine Calcium/creatinine ratio is done at
least once a month (before pamidronate administration) while
X-ray skeletal survey--before treatment and then every six
months. RESULTS: In the first months of treatment apparent
reduction of bone pain occurred. Hypercalcaemia was revealed in
6 patients at entry into the study. In 5 of these patients
pamidronate restored and maintained normocalcaemia for a median
6 months. In 3 patients an aggressive plasma cell
proliferation was accompanied by reoccurrence of hypercalcaemia. At
skeletal X-ray examination performed after 6 and 12 cycles of
pamidronate and by comparing each of consecutive imaging with
previous one the progression of osteolysis was respectively found
in 67% and 39% of patients. In the control group corresponding
figures were: 79% and 70%. The mean number of skeletal events
(pathologic fracture, radiation to bone and spinal cord compression)
per year was lower in the pamidronate group (1.82) than in
control-patients (2.72) , p 0.013. The proportion of patients who
developed skeletal event (excluding vertebral fractures) was
lower in the pamidronate group -34% v 52%. Adverse events of
pamidronate: hypocalcaemia ( 2 mmol/l) observed in 7 patients
occurred in particular patients beginning from 2 to 7 days after
drug administration. In 2 patients hypocalcaemia that appeared in
24 hours after drug infusion was accompanied by blood pressure
decrease; in one case systolic blood pressure dropped up to 60
mmHg, in the other one--to 90 mmHg. Muscular pain and fever up to
39 degrees C (transient and self-limiting "influenza like
syndrom") occurred in 5 patients, in two patients after several hours
and in three other--after some dozens of hours from drug
administration. In one case hypertransaminasaemia was observed.
CONCLUSIONS: In the first year of treatment monthly
intravenous pamidronate administration as an adjunct to
chemotherapy in patients with advanced multiple myeloma with
osteolysis is an efficient approach in prevention and
treatment of hyperacalcaemia, hypercalciuria and bone pain. It
also shows some preventive effect on bone lesion occurrence. PT
Clinical-Trial, Journal-Article, Randomized-Controlled-Trial. ED
20010503.';
if (preg_match('/(.|[\r\n])+/', $x)):
$y = 1;
endif;
?>
------------------------------------------------------------------------
--
Edit this bug report at http://bugs.php.net/?id=19386&edit=1
